[Effect of proteasome inhibitor on migration ability and hepatocyte growth factor expression of bone marrow mesenchymal stem cells in multiple myeloma patients].

Abstract

This study was aimed to investigate the effect of proteasome inhibitor bortezomib on the migration ability and hepatocyte growth factor (HGF) expression of bone marrow mesenchymal stem cells (MSC) in multiple myeloma patients. Transwell assay was employed to measure the migration ability of bone marrow MSC in vitro before and after treatment with bortezomib. The HGF mRNA expression level was determined by real-time quantitative PCR. The results indicated that after treated with bortezomib of concentrations of 2.5 nmol/L for 48 hours, the migration activity of MSC decreased significantly as compared with control cohorts (p < 0.05). The HGF mRNA level in MSC after bortezomib treatment was significantly lower than that of control group (p < 0.05). It is concluded that bortezomib can inhibit the migration and down-regulate HGF mRNA expression of bone marrow MSC in multiple myeloma patients.

• Authors: Jun-Xia Li, Xiao-Ming Fei, Hua Lu, Hui-Jin Hu, Jian-Yong Li
• Journal: Zhongguo shi yan xue ye xue za zhi (Zhongguo Shi Yan Xue Ye Xue Za Zhi) Vol. 19 Issue 5 Pg. 1204-8 (Oct 2011) ISSN: 1009-2137 [Print] China
• PMID: 22040972 (Publication Type: Journal Article, Research Support, U.S. Gov't, Non-P.H.S.)

Chemical References

• Antineoplastic Agents
• Boronic Acids
• Proteasome Inhibitors
• Pyrazines
• Hepatocyte Growth Factor
• Bortezomib

Topics

• Adult
• Antineoplastic Agents (pharmacology)
• Bone Marrow Cells (cytology, drug effects)
• Boronic Acids (pharmacology)
• Bortezomib
• Cell Movement (drug effects)
• Female
• Hepatocyte Growth Factor (metabolism)
• Humans
• Male
• Mesenchymal Stem Cells (cytology, drug effects)
• Middle Aged
• Multiple Myeloma (metabolism)
• Proteasome Inhibitors (pharmacology)
• Pyrazines (pharmacology)